Pathogens, Год журнала: 2024, Номер 14(1), С. 8 - 8

Опубликована: Дек. 27, 2024

Due to the lack of agents that directly target covalently closed circular DNA and integrated HBV in hepatocytes, achieving a complete cure for chronic hepatitis B (CHB) remains challenging. The latest guidelines recommend (hepatitis surface antigen) HBsAg loss as ideal treatment improving liver function, histopathology, long-term prognosis. However, even after loss, virus can persist, with risk recurrence, reactivation, cirrhosis, hepatocellular carcinoma. Therefore, follow-up surveillance are still necessary. With increasing options available patients CHB, developing effective strategies has become crucial. Recent studies on outcomes following provide new insights refining current strategies, though further improvement is needed through observation follow-up.

Язык: Английский